-

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exscientia p.l.c. (EXAI)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 25, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) securities between March 23, 2022 and February 12, 2024, inclusive (the “Class Period”).

If you suffered a loss on your Exscientia investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/Exscientia-plc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On February 13, 2024, Exscientia announced that its CEO and Principal Executive Officer, Andrew Hopkins, had been terminated following an investigation which found that he had “engaged in relationships with two employees that the Board determined were inappropriate and inconsistent with the Company’s standards and values.” The Company also disclosed that the Chairman of the Company’s Board of Directors, David Nicholson, “had prior knowledge of the existence of the earlier of Dr. Hopkins’ relationships and had addressed the situation directly, and with the involvement of other outside counsel, rather than in consultation with the Board,” and “[f]ollowing discussions with the Board, on February 12, 2024 Dr. Nicholson tendered his resignation from his positions with the Company.”

On this news, Exscientia’s stock price fell $1.72, or 22.9%, to close at $5.79 per share on February 13, 2024, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Defendant Hopkins had engaged in improper relationships with employees that were inconsistent with the Company’s standards and values; (2) Defendant Nicholson had prior knowledge of Defendant Hopkins’s relationships and had improperly addressed Hopkins’s misconduct without consulting the Board; (3) the Company’s maintenance and enforcement of its Code of Business Conduct and Ethics was inadequate to safeguard against the foregoing conduct; (4) the foregoing failures subjected the Company to a heightened risk of disruptive leadership transitions and/or reputational harm; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Exscientia securities during the Class Period, you may move the Court no later than June 25, 2024 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

Glancy Prongay & Murray LLP

NASDAQ:EXAI

Release Versions

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

More News From Glancy Prongay & Murray LLP

Deadline Alert: F5, Inc. (FFIV) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming February 17, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired F5, Inc. (“F5” or the “Company”) (NASDAQ: FFIV) securities between October 28, 2024 and October 27, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR F5 INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LO...

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Encourages SLM Corporation (SLM) Shareholders to Inquire About Securities Fraud Class Action

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired SLM Corporation a/k/a Sallie Mae (“SLM” or the “Company”) (NASDAQ: SLM) securities between July 25, 2025 and August 14, 2025, inclusive (the “Class Period”). SLM investors have until February 17, 2026 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON...

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Charming Medical Limited (MCTA) Shareholders to Inquire About Securities Fraud Class Action

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Charming Medical Limited (“Charming” or the “Company”) (NASDAQ: MCTA) securities between October 10, 2025 and November 12, 2025, inclusive (the “Class Period”). Charming investors have until February 17, 2026 to file a lead plaintiff motion. IF YOU SUFFERED A...
Back to Newsroom